A Phase 1 Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors With BRCA1/2 Mutations or Other DDR Deficiencies or High Replication Stress.
This study is testing an experimental drug called FORX-428 to see if it can safely stop the growth of advanced solid tumors. Researchers are specifically looking for patients whose cancers have certain gene changes that make it difficult for cells to repair their own DNA.
This trial is for adults 18 or older with advanced cancer that has not responded to or has spread after standard treatments. Participants must have specific genetic markers in their tumor or blood, such as BRCA1 or BRCA2 mutations, and must meet certain general health requirements.
As this is an early-stage study, researchers will carefully give increasing doses of FORX-428 to small groups of patients to find the safest and most effective amount. You will be closely monitored by a medical team throughout the process to track how your body responds to the new medication.
The study is currently recruiting patients at medical centers in Palo Alto, California; San Francisco, California; and Grand Rapids, Michigan.
- 1The study tests a new drug called FORX-428 for advanced cancers.
- 2You must have specific genetic markers related to DNA repair to join.
- 3The primary goal is to find the right dose while keeping patients safe.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.